227 related articles for article (PubMed ID: 8091766)
41. Treatment of tumor-induced osteolysis by APD.
Burckhardt P; Thiébaud D; Perey L; von Fliedner V
Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
[TBL] [Abstract][Full Text] [Related]
42. Safety of pamidronate in patients with renal failure and hypercalcemia.
Machado CE; Flombaum CD
Clin Nephrol; 1996 Mar; 45(3):175-9. PubMed ID: 8706358
[TBL] [Abstract][Full Text] [Related]
43. Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
Huang CY; Zheng CM; Wu CC; Lo L; Lu KC; Chu P
Nephron Clin Pract; 2012; 122(3-4):93-101. PubMed ID: 23635416
[TBL] [Abstract][Full Text] [Related]
44. Urine calcium and serum ionized calcium, total calcium and parathyroid hormone concentrations in the diagnosis of primary hyperparathyroidism and familial benign hypercalcaemia.
Gunn IR; Wallace JR
Ann Clin Biochem; 1992 Jan; 29 ( Pt 1)():52-8. PubMed ID: 1536526
[TBL] [Abstract][Full Text] [Related]
45. Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.
Khan A; Bilezikian J; Bone H; Gurevich A; Lakatos P; Misiorowski W; Rozhinskaya L; Trotman ML; Tóth M
Eur J Endocrinol; 2015 May; 172(5):527-35. PubMed ID: 25637076
[TBL] [Abstract][Full Text] [Related]
46. Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population-based screening 8 years ago.
Lundgren E; Hagström EG; Lundin J; Winnerbäck K; Roos J; Ljunghall S; Rastad J
World J Surg; 2002 Aug; 26(8):931-6. PubMed ID: 12045863
[TBL] [Abstract][Full Text] [Related]
47. Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate.
Shane E; Jacobs TP; Siris ES; Steinberg SF; Stoddart K; Canfield RE; Bilezikian JP
Am J Med; 1982 Jun; 72(6):939-44. PubMed ID: 6211978
[TBL] [Abstract][Full Text] [Related]
48. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
J Clin Oncol; 1988 May; 6(5):762-8. PubMed ID: 3367184
[TBL] [Abstract][Full Text] [Related]
49. Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD.
Papapoulos SE; Harinck HI; Bijvoet OL; Gleed JH; Fraher LJ; O'Riordan JL
Bone Miner; 1986 Feb; 1(1):69-78. PubMed ID: 3508718
[TBL] [Abstract][Full Text] [Related]
50. Long-term effects of parathyroid operation on serum calcium and parathyroid hormone values in sporadic primary hyperparathyroidism.
Lundgren E; Rastad J; Ridefelt P; Juhlin C; Akerström G; Ljunghall S
Surgery; 1992 Dec; 112(6):1123-9. PubMed ID: 1455314
[TBL] [Abstract][Full Text] [Related]
51. [[Clodronate therapy of hypercalcemia caused by hyperparathyroidism].
Hoffmeyer P; Groebli Y; Spiliopoulos A; Jung A
Schweiz Med Wochenschr; 1982 Jan; 112(4):118-20. PubMed ID: 6461066
[TBL] [Abstract][Full Text] [Related]
52. Serum calcium (S-Ca), the forgotten test: preliminary results of an appropriateness strategy to detect primary hyperparathyroidism (pHPT).
Salinas M; López-Garrigós M; Pomares F; Lugo J; Asencio A; López-Penabad L; Dominguez JR; Leiva-Salinas C
Bone; 2013 Sep; 56(1):73-6. PubMed ID: 23707628
[TBL] [Abstract][Full Text] [Related]
53. Calcium clamp technique: suppression of serum intact PTH by induced hypercalcaemia in normal man and primary hyperparathyroidism.
Sørensen HA; Schwarz P; McNair P; Hyldstrup L; Transbøl I
Scand J Clin Lab Invest; 1992 Oct; 52(6):457-65. PubMed ID: 1411258
[TBL] [Abstract][Full Text] [Related]
54. Familial idiopathic hyperphosphatasia (FIH): response to long-term treatment with pamidronate (APD).
Cassinelli HR; Mautalen CA; Heinrich JJ; Miglietta A; Bergada C
Bone Miner; 1992 Nov; 19(2):175-84. PubMed ID: 1422313
[TBL] [Abstract][Full Text] [Related]
55. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
Budayr AA; Zysset E; Jenzer A; Thiébaud D; Ammann P; Rizzoli R; Jaquet-Müller F; Bonjour JP; Gertz B; Burckhardt P
J Bone Miner Res; 1994 Apr; 9(4):521-6. PubMed ID: 8030440
[TBL] [Abstract][Full Text] [Related]
56. Suppression by calcium of serum levels of intact parathyroid hormone in patients with primary hyperparathyroidism.
Bergenfelz A; Valdermarsson S; Ahrén B
Horm Res; 1993; 39(3-4):146-51. PubMed ID: 8262476
[TBL] [Abstract][Full Text] [Related]
57. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
Body JJ; Borkowski A; Cleeren A; Bijvoet OL
J Clin Oncol; 1986 Aug; 4(8):1177-83. PubMed ID: 3016205
[TBL] [Abstract][Full Text] [Related]
58. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
Gucalp R; Theriault R; Gill I; Madajewicz S; Chapman R; Navari R; Ahmann F; Zelenakas K; Heffernan M; Knight RD
Arch Intern Med; 1994 Sep; 154(17):1935-44. PubMed ID: 8074597
[TBL] [Abstract][Full Text] [Related]
59. [Primary hyperparathyroidism. Lack of effect of cimetidine on plasma levels of parathyroid hormone and calcium].
Line D; Sebert JL; Grégoire I; Gueris J; Pruna A; Bourdeau A; Hervé MA; Hardin JM; Fournier A
Presse Med; 1984 Mar; 13(12):727-30. PubMed ID: 6231577
[TBL] [Abstract][Full Text] [Related]
60. Long-Term Use of Cinacalcet in Kidney Transplant Recipients With Hypercalcemic Secondary Hyperparathyroidism: A Single-Center Prospective Study.
Zavvos V; Fyssa L; Papasotiriou M; Papachristou E; Ntrinias T; Savvidaki E; Goumenos DS
Exp Clin Transplant; 2018 Jun; 16(3):287-293. PubMed ID: 29108515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
